NEWS
FIRST-OF-ITS-KIND STUDY EVALUATES LINK BETWEEN SHINGLES VACCINE AND REDUCED RISK OF DEMENTIA THROUGH A HEALTH DATA ECOSYSTEM
GSK has announced a major new research collaboration with the UK DRI and HDR UK to advance understanding of neurodegeneration with a first-of-its-kind dementia study. of dementia is much needed but challenging given the multiple, complex factors which may contribute to the development of the disease.
Professor Andrew Morris, Director of Health Data Research UK, said:“ Dementia represents one of the greatest challenges of our time, affecting millions of families across the UK and beyond. By working closely with the NHS in the four UK nations to ensure data privacy and security, we can enable prevention-focused research, deepen our understanding of disease and support the NHS in shifting from treating sickness to keeping people healthier for longer – helping them live better lives.”
The innovative project aims to use the UK’ s health data ecosystem to explore a potential association between GSK’ s shingles vaccine, Recombinant Zoster Vaccine( RZV), and a reduced risk of dementia. If successful, this could serve as a blueprint for population level health data research models, reinforcing the UK’ s position as a leading destination for scientific research.
More than 55 million people worldwide have dementia, with cases increasing as the global population ages. Research to identify potential opportunities to reduce the risk
JOHNSON & JOHNSON MEDTECH ANNOUNCES CLEARANCE OF MONARCHTM QUEST FOR ENHANCED ROBOTIC- ASSISTED BRONCHOSCOPY
Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, has announced US 510( k) regulatory clearance for MONARCH QUEST, the latest advancement in MONARCH navigation technology, featuring AI-powered algorithms and a verified OEC Open interface with the GE HealthCare OEC 3D mobile CBCT Imaging System.
Robotically-assisted bronchoscopy represents a small but fast-growing segment of lung biopsy procedures in the US. The MONARCH Platform, the first robotically assisted bronchoscopy system to market, provides minimally invasive access to and visualisation of airways to help clinicians biopsy suspicious lung nodules.
Nearly half of early-stage lesions are located in the periphery of the lung, which is difficult to reach with traditional bronchoscopy. The MONARCH Platform can aid clinicians in getting to an early, definitive diagnosis in lung cancer cases, which can help care teams get patients into the treatment pathway an average of three weeks faster.
“ Our goal with the MONARCH Platform is to change the treatment paradigm for diseases such as lung cancer, where significant unmet needs still remain,” said Aleksandra Popovic, President, MONARCH, Johnson & Johnson MedTech.“ MONARCH QUEST demonstrates our commitment to delivering meaningful innovation that helps clinicians advance the standard of care for their patients.”
www. intelligenthealth. tech 7